Phase 3 Degeneration Clinical Trials
30 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 30 trials
Recruiting
Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled79 locationsNCT07482176
Recruiting
Phase 2Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Age-Related Macular DegenerationMacular DegenerationChoroidal Neovascularization+1 more
EyeBiotech Ltd.960 enrolled56 locationsNCT07496567
Recruiting
Phase 2Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Age-Related Macular DegenerationMacular DegenerationChoroidal Neovascularization+1 more
EyeBiotech Ltd.960 enrolled87 locationsNCT07440225
Recruiting
Phase 3
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular DegenerationnAMD
Amgen304 enrolled29 locationsNCT07614776
Recruiting
Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled218 locationsNCT06541704
Recruiting
Phase 3
Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
SANGMYUNG innovation266 enrolled1 locationNCT07695207
Recruiting
Phase 3
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular DegenerationnAMD
Hoffmann-La Roche68 enrolled16 locationsNCT05562947
Recruiting
Phase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
AbbVie561 enrolled128 locationsNCT07007065
Recruiting
Phase 3
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche1,000 enrolled165 locationsNCT03683251
Recruiting
Phase 3
MDT-0123 Japan Study
Disc DegenerationSpinal Deformity
Medtronic Spinal and Biologics140 enrolled14 locationsNCT07414745
Recruiting
Phase 3
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Neovascular Age-Related Macular Degeneration (nAMD)
Ocular Therapeutix, Inc.850 enrolled8 locationsNCT07516132
Recruiting
Phase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche250 enrolled59 locationsNCT06847542
Recruiting
Phase 3
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Neovascular Age-related Macular Degeneration
Jaeb Center for Health Research600 enrolled65 locationsNCT05904028
Recruiting
Phase 3
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
Eye DiseasesMacular Degeneration, WetSub-Macular Hemorrhage
King's College Hospital NHS Trust210 enrolled36 locationsNCT04663750
Recruiting
Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
wet age related macular degenerationAMDnAMD+3 more
AbbVie714 enrolled181 locationsNCT05407636
Recruiting
Phase 3
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics480 enrolled94 locationsNCT07064759
Recruiting
Phase 3
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
Age-Related Macular DegenerationPolypoidal Choroidal Vasculopathy (PCV)
Yeungnam University College of Medicine50 enrolled1 locationNCT07461441
Recruiting
Phase 3
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Innostellar Biotherapeutics Co.,Ltd332 enrolled31 locationsNCT07317934
Recruiting
Phase 3
Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
Down Syndrome (DS)KeratoconusForme Fruste Keratoconus (FFK)+1 more
Woolfson Eye Institute225 enrolled12 locationsNCT07135167
Recruiting
Phase 3
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
KeratoconusEctasia of CorneaPellucid Marginal Corneal Degeneration+1 more
Woolfson Eye Institute485 enrolled12 locationsNCT07124910